Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109499 · ClinicalTrials.gov registry record · Phase 1
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
A Phase 1 study, sponsored by GenVec.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00109499 is a Phase 1 study that has completed, run by GenVec.
The verdict
NCT00109499, a Phase 1 study, has completed, sponsored by GenVec.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The primary purpose of this study is to assess the safety of AdGVPEDF.11D when given to patients with "wet" age-related macular degeneration (AMD). AdGVPEDF.11D is a replication deficient (E1, E3 and E4 deleted) adenovirus vector containing the gene for the PEDF (pigment epithelium-derived factor) protein. PEDF is a protein that naturally exists in the human eye, but whose levels are altered in diseases characterized by ocular neovascularization like AMD. The PEDF protein is known to have anti-angiogenic effects or, in other words, it has the ability to inhibit growth of new blood vessels. AdGVPEDF.11D will be delivered once via intravitreal injection into one eye. The injected eye will be the eye with the worst visual acuity.
Interventions
- DRUG AdGVPEDF.11D
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109499
The ClinicalTrials.gov registry entry for NCT00109499 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is GenVec, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AdGVPEDF.11D is the first listed.
NCT00109499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109499 about?
NCT00109499 is a clinical study titled "Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)". The primary purpose of this study is to assess the safety of AdGVPEDF.11D when given to patients with "wet" age-related macular degeneration (AMD). AdGVPEDF.11D is a replication deficient (E1, E3 and E4 deleted) adenovirus vector containing the gene for the PEDF (pigment epithelium-derived factor) p...
What is the current status of trial NCT00109499?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00109499?
The interventions under investigation include: AdGVPEDF.11D (DRUG).
Who is sponsoring clinical trial NCT00109499?
This trial is sponsored by GenVec, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.